The Raynauds Disease drugs in development market research report provides comprehensive information on the therapeutics under development for Raynauds Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Raynauds Disease. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Raynauds Disease and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Raynauds Disease by seven companies/universities/institutes. The top development phase for Raynauds Disease is phase ii with four drugs in that stage. The Raynauds Disease pipeline has six drugs in development by companies and one by universities/ institutes. Some of the companies in the Raynauds Disease pipeline products market are: Camurus, University of Toledo and Seelos Therapeutics.
The key targets in the Raynauds Disease pipeline products market include Prostaglandin E2 Receptor EP1 Subtype (Prostanoid EP1 Receptor or PTGER1), Prostaglandin E Synthase (Microsomal Glutathione S Transferase 1 Like 1 or Microsomal Prostaglandin E Synthase 1 or p53 Induced Gene 12 Protein or PTGES or EC 5.3.99.3), and Prostacyclin Receptor (Prostaglandin I2 Receptor or Prostanoid IP Receptor or PTGIR).
The key mechanisms of action in the Raynauds Disease pipeline product include Prostaglandin E2 Receptor EP1 Subtype (Prostanoid EP1 Receptor or PTGER1) Agonist with two drugs in Phase II. The Raynauds Disease pipeline products include three routes of administration with the top ROA being Topical and one key molecule types in the Raynauds Disease pipeline products market including Small Molecule.
Raynauds Disease overview
Raynauds disease is a common condition that affects the blood supply to certain parts of the body, usually the fingers and toes. Predisposing factors include age, gender, family history, and smoking. Symptoms include fingers, toes, ears, or nose turning white and then blue. Treatment includes vasodilators, alpha blockers, and calcium channel blockers.
For a complete picture of Raynauds Disease’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
